Basit öğe kaydını göster

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorEser, Bulent
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorTiryaki, Tarik Onur
dc.contributor.authorUlas, Turgay
dc.contributor.authorÖZATLI, DÜZGÜN
dc.contributor.authorAkpinar, Seval
dc.contributor.authorDogu, Mehmet Hilmi
dc.contributor.authorÇELİK, SERHAT
dc.contributor.authorEkinci, Omer
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorDavulcu, Eren Arslan
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorHindilerden, Fehmi
dc.contributor.authorOzcan, Busra Gokce
dc.contributor.authorHACIBEKİROĞLU, TUBA
dc.contributor.authorERKURT, MEHMET ALİ
dc.contributor.authorBagci, Metin
dc.contributor.authorNamdaroglu, Sinem
dc.contributor.authorKorkmaz, Gulten
dc.contributor.authorBilgir, Oktay
dc.contributor.authorÇAĞLIYAN, GÜLSÜM AKGÜN
dc.contributor.authorOzturk, Hacer Berna Afacan
dc.contributor.authorSerin, Istemi
dc.contributor.authorTURGUT, BURHAN
dc.date.accessioned2022-07-04T16:28:53Z
dc.date.available2022-07-04T16:28:53Z
dc.date.issued2022
dc.identifier.citationAkpinar S., Dogu M. H. , ÇELİK S., Ekinci O., Hindilerden I. Y. , Dal M. S. , Davulcu E. A. , Tekinalp A., Hindilerden F., Ozcan B. G. , et al., "The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL", CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.22, sa.3, ss.169-173, 2022
dc.identifier.issn2152-2650
dc.identifier.otherav_e76d5d2b-0c13-4e76-960a-d4f1c2ceb72d
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/185157
dc.identifier.urihttps://doi.org/10.1016/j.clml.2021.09.010
dc.description.abstractWe evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.
dc.language.isoeng
dc.subjectHealth Sciences
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHematology
dc.subjectTıp
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectHematoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectSağlık Bilimleri
dc.titleThe Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
dc.typeMakale
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
dc.contributor.departmentOndokuz Mayıs Üniversitesi , ,
dc.identifier.volume22
dc.identifier.issue3
dc.identifier.startpage169
dc.identifier.endpage173
dc.contributor.firstauthorID3398178


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster